• Publications
  • Influence
Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma.
TLDR
The addition of temozolomide to radiotherapy for newly diagnosed glioblastoma resulted in a clinically meaningful and statistically significant survival benefit with minimal additional toxicity. Expand
Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial.
TLDR
Benefits of adjuvant temozolomide with radiotherapy lasted throughout 5 years of follow-up, and a benefit of combined therapy was recorded in all clinical prognostic subgroups, including patients aged 60-70 years. Expand
MGMT gene silencing and benefit from temozolomide in glioblastoma.
TLDR
Patients with glioblastoma containing a methylated MGMT promoter benefited from temozolomide, whereas those who did not have a methylation of theMGMT promoter did notHave such a benefit and were assigned to only radiotherapy. Expand
An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor
TLDR
Evidence is provided for a previously unidentified pathophysiological function of the AHR that is constitutively generated by human tumours via tryptophan-2,3-dioxygenase (TDO), a liver- and neuron-derived Trp-degrading enzyme not yet implicated in cancer biology. Expand
Type and frequency of IDH1 and IDH2 mutations are related to astrocytic and oligodendroglial differentiation and age: a study of 1,010 diffuse gliomas
TLDR
An inverse association of IDH1 and IDH2 mutations of the R132C type are strongly associated with astrocytoma, while IDH 2 mutations predominantly occur in oligodendroglial tumors. Expand
Correlation of O6-methylguanine methyltransferase (MGMT) promoter methylation with clinical outcomes in glioblastoma and clinical strategies to modulate MGMT activity.
TLDR
The data supporting MGMT as a major mechanism of chemotherapy resistance in malignant gliomas is reviewed and ongoing studies that are testing resistance-modulating strategies are described. Expand
NOA-04 randomized phase III trial of sequential radiochemotherapy of anaplastic glioma with procarbazine, lomustine, and vincristine or temozolomide.
TLDR
IDH1 mutations are a novel positive prognostic factor in anaplastic gliomas, with a favorable impact stronger than that of 1p/19q codeletion or MGMT promoter methylation and associated with prolonged PFS in the chemotherapy and radiotherapy arm. Expand
Temozolomide chemotherapy alone versus radiotherapy alone for malignant astrocytoma in the elderly: the NOA-08 randomised, phase 3 trial.
TLDR
Temozolomide alone is non-inferior to radiotherapy alone in the treatment of elderly patients with malignant astrocytoma and MGMT promoter methylation seems to be a useful biomarker for outcomes by treatment and could aid decision-making. Expand
Molecular predictors of progression-free and overall survival in patients with newly diagnosed glioblastoma: a prospective translational study of the German Glioma Network.
TLDR
Molecular changes associated with gliomagenesis do not predict response to therapy in glioblastoma patients managed according to current standards of care and MGMT promoter methylation and IDH1 mutational status allow for stratification into prognostically distinct subgroups. Expand
Neuroprotection by Hypoxic Preconditioning Requires Sequential Activation of Vascular Endothelial Growth Factor Receptor and Akt
TLDR
An invitro model of hypoxic neuroprotection in cerebellar granule neurons is developed and a sequential requirement for VEGF/VEGFR-2 activation and Akt/PKB phosphorylation for neuronal survival mediated by hypoxic preconditioning is indicated and V EGF is proposed as a hypoxia-induced neurotrophic factor. Expand
...
1
2
3
4
5
...